Cendifensine

Cendifensine

Clinical data
Drug class	Monoamine reuptake inhibitor
Identifiers
IUPAC name (3,4-dichlorophenyl)-[(3S)-3-propylpyrrolidin-3-yl]methanone
CAS Number	1034048-49-1
PubChem CID	59744668
UNII	N4U2JR8GCX
Chemical and physical data
Formula	C14H17Cl2NO
Molar mass	286.20 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC[C@@]1(CCNC1)C(=O)C2=CC(=C(C=C2)Cl)Cl
InChI InChI=1S/C14H17Cl2NO/c1-2-5-14(6-7-17-9-14)13(18)10-3-4-11(15)12(16)8-10/h3-4,8,17H,2,5-7,9H2,1H3/t14-/m0/s1 Key:HVLPRTLORBIKNG-AWEZNQCLSA-N

Cendifensine (INN Tooltip International Nonproprietary Name) is a monoamine reuptake inhibitor (MRI) ^[1] related to the amphetamines and cathinones which has not been marketed at this time. ^{[2] [3] [4]} It was first described by 2013 ^[4] and its INN Tooltip International Nonproprietary Name was proposed in 2024. ^[2] The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms as well as for binge-eating disorder and depressive disorders. ^{[5] [6] [7]}

See also

• 3,4-Dichloroamphetamine
• Bupropion
• Lafadofensine
• Org 6582

References

1. WO 2023/161533A1,Garibaldi G,"Triple uptake inhibitor for the treatment of atypical depression",published 31 August 2023, assigned to Noema Pharma AG 
2. "Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (4). 2024. cendifensinum cendifensine (3,4-dichlorophenyl)[(3S)-3-propylpyrrolidin-3-yl]methanone monoamine reuptake inhibitor [...] C14H17Cl2NO 1034048-49-1
3. "(3,4-Dichlorophenyl)[(3S)-3-propyl-3-pyrrolidinyl]methanone". Global Substance Registration System (GSRS). National Center for Advancing Translational Sciences (NCATS), U.S. National Institutes of Health. Retrieved 24 February 2025.
4. CA 2860810A1,Adam JM, Dvorak CA, Fishlock D, Humphreys ER, Iding H, Pfleger C, Rege PD, Shi X, Vitale J, Wang S, Zajac M,"(3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes",published 23 April 2013, assigned to F Hoffmann La Roche AG 
5. "NOE 115". AdisInsight. 21 May 2024. Retrieved 24 February 2025.
6. "Delving into the Latest Updates on Noema Pharma AG with Synapse". Synapse. 23 January 2025. Retrieved 24 February 2025.
7. "Noema Pharma". Noema Pharma. 18 June 2021. Retrieved 24 February 2025.